OOIR: Observatory of International Research

Papers

(The median citation count of Cytometry Part B-Clinical Cytometry is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Monitoring CAR T‐cells using flow cytometry	44
Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics	29
Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T‐cell clonality and diagnosis of T‐cell<	28
New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry	28
High‐sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events	26
Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping	24
Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes	24
Monitoring CAR‐T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challenges	21
CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab	20
A flow cytometric assay for HLA‐DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials	20
Determination of CD43 and CD200 surface expression improves accuracy of B‐cell lymphoma immunophenotyping	19
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses	19
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow	17
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet	16
An easy and reliable whole blood freezing method for flow cytometry immuno‐phenotyping and functional analyses	16
Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26− or CD7−	15
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact	14
ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry	14
Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry	13
Eleven‐marker 10‐color flow cytometric assessment of measurable residual disease for T‐cell acute lymphoblastic leukemia using an approach of exclusion	13
Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry	13
ESCCA/ISCCA protocol for the analysis of cerebrospinal fluid by multiparametric flow‐cytometry in hematological malignancies	12
Chimerism evaluation in measurable residual disease‐suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allog	12
Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints	12
Single‐cell profiling of pediatric T‐cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK–STAT signaling pathways	12

Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes	11
New cytometry tools for immune monitoring during cancer immunotherapy	11
B‐lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting	11
Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma	10
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by theELN iMDSflow working group	10
Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machine‐learning assisted morphometrics	10
Increased expression of immune checkpoint programmed cell death protein‐1 (PD‐1) on T cell subsets of bone marrow aspirates in patients with B‐Lymphoblastic leukemia, especially	10
Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes	10
Peripheral innate and adaptive immune cells during COVID‐19: Functional neutrophils, pro‐inflammatory monocytes, and half‐dead lymphocytes	10
Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells	10
Flow cytometric method transfer: Recommendations for best practice	10
14‐Color single tube for flow cytometric characterization of CD5+ B‐LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL	10
Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MD	10
Immunophenotypic shift in the B‐cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B‐lymphoblastic leukemia	9
Performance of eight‐color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples	9
Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through ass	9
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis	9
The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms	9
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues	9
Increased TOX expression concurrent with PD‐1, Tim‐3, and CD244 expression in T cells from patients with acute myeloid leukemia	9
A multicenter study evaluation of the ClearLLab 10C panels	8
Illuminating the immunopathology of SARS‐CoV‐2	8
Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution	8
FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study	8
Characterization of KIR + NKG2A + Eomes− NK‐like CD8+ T cells and their decline with age in healthy individuals	8
Leukocyte immunoglobulin‐like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation	8
Relevance of polyclonal plasma cells and post‐therapy immunomodulation in measurable residual disease assessment in multiple myeloma	8
Clinical and laboratory features associated with myeloperoxidase expression in pediatric B‐lymphoblastic leukemia	8
Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry	8
Development and validation of a high‐parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease	7
Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse larg	7
Steric hindrance: A practical (and frequently forgotten) problem in flow cytometry	7
The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes	7
Utility of CD36 as a novel addition to the immunophenotypic signature of RAM‐phenotype acute myeloid leukemia and study of its clinicopathological characteristics	7
Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy	7
Characteristic CD45RA/CD45RO maturation pattern by flow cytometry associated with the CD45 C77G polymorphism	7
The ISCCA flow protocol for the monitoring of anti‐CD20 therapies in autoimmune disorders	7
International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality moni	7
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience	6
A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: A case report	6
Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern‐based recognition	6
Flow cytometry‐based analysis of tumor‐leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer	6
Bicentric evaluation of stabilizing sampling tubes for assessment of monocyte HLA‐DR expression in clinical samples	6
Machine learning optimized multiparameter radar plots for B‐cell acute lymphoblastic leukemia minimal residual disease analysis	6
Best practices for optimization and validation of flow cytometry‐based receptor occupancy assays	5
Analysis of human chromosomes by imaging flow cytometry	5
Diagnostic performance of the ClearLLab 10C B cell tube	5
Refractory neutrophils and monocytes in patients with inflammatory bowel disease after repeated bouts of prolonged exercise	5
Sudden blast phase in pediatric chronic myeloid leukemia‐chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?	5
Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy	5

Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review	5
Validation of inducible basophil biomarkers: Time, temperature and transportation	5
PD‐1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome	5
Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples	5
Evaluation of B‐cell intracellular signaling by monitoring the PI3K‐Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3‐kinase delta syndrome	5
Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories	5
Erroneous expression of NKG2D on granulocytes detected by phycoerythrin‐conjugated clone 149810 antibody	4
A comparison and review of the flow cytometric findings in classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, T cell/histiocyte rich large B cell lymphoma, and primary mediasti	4
Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors	4
Diagnostic utility of flow cytometry based coated‐platelets assay as a biomarker to predict thrombotic or hemorrhagic phenotype in acute stroke	4
Human leukocyte antigen‐B27 typing by flow cytometry: Comparison of three CE‐IVD methods	4
Resolving 31 colors on a standard 3‐laser full spectrum flow cytometer for immune monitoring of human blood samples	4
Validation of a new multiparametric protocol to assess viability, acrosome integrity and mitochondrial activity in cooled and frozen thawed boar spermatozoa	4
CLL/SLL specifically binding to the APC fluorochrome: A previously undescribed phenomenon	4
Circulating CD22+/CD19−/CD24− progenitors and CD22+/CD19+/CD24− mature B cells: Diagnostic pitfalls for minimal residual disease detec	4
Comparison of three methods to stabilize bronchoalveolar lavage cells for flowcytometric analysis	4
A series of case studies illustrating the role of flow cytometry in the diagnostic work‐up of myelodysplastic syndromes	4
Occurrence of T‐cell and NK‐cell subsets with less well‐recognized phenotypes in peripheral blood submitted for routine flow cytometry analysis	4
Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR‐ABL1, KMT2A rearrangement, and other adult B‐cell precursor	4
Correlation between a 10‐color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B‐acute lymphoblastic leukemia	4
Use of flow cytometry and cytology to differentiate breast implant‐associated anaplastic large cell lymphoma from reactive seromas in Brazilian patients	4
Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic Flow‐Self Organizing Maps algorithm	4
Quick identification of target antigens by tissue flow cytometry for CAR‐T therapy in B‐cell malignancies	3
Genomic profile of TdT^positiveMYC/BCL2 rearranged high‐grade B‐cell lymphoma supporting its diagnosis as mature aggressive lymphoma	3
CD4+ T‐cell large granular lymphocytic leukemia with STAT3 mutation and neutropenia	3
Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy	3
Prognostic significance of hematogone presence after autologous stem cell transplantation in patients with multiple myeloma	3
Time point‐dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia wit	3
Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma	3
Spurious CD34 expression in B‐cell lymphoma due to nonspecific binding to PerCP‐Cy5.5 fluorochrome conjugates: A rare phenomenon and a diagnostic pitfall	3
Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contrib	3
CD69flow cytometry to complement interferon‐γrelease assay for active tuberculosis	3
Letter to the editor with regard to the article entitled “Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping”	3
Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non‐Hodgkin lymphoma	3
Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection	3
Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry	3
Combined use of different antibody clones improves the efficiency of human leukocyte antigen B27 detection by flow cytometry	3
Abnormal B‐lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia	2
Reactive oxygen species levels differentiate CD34⁺ human progenitors based on CD38 expression	2
An unusual case of cytoplasmic CD3 expressing BPDCN supporting the T‐lineage origin of plasmacytoid dendritic cells	2
Partial recapitulation of fetal thymic T‐cell constitution postnatally in a patient with cartilage hair hypoplasia‐anauxetic dysplasia spectrum disorder: A case report	2
Characteristic flow cytometric profile of ectopic intra‐thyroidal thymic tissue in children	2
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry	2
Dissecting the sCD3‐CD4+ T‐cell population: A valuable screening tool for angioimmunoblastic T‐cell lymphoma	2
CD200 expression on Sezary cells: A valuable tool for flow cytometric assessment of peripheral blood T‐cell neoplasms	2
Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B‐cell acute lymphoblastic leukemia using multicolor flow cytometry	2
Reactive NK cell lymphocytosis with atypical immunophenotype in a chronic HIV‐infected patient	2
Standardization of flow cytometric detection of antigen expression	2
Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential pre‐myelomastocytic leukemia condition	2
Monitoring of tumor cells by flow cytometry permits rapid evaluation of disease progression in monomorphic epitheliotropic intestinal T‐cell lymphoma	2
Blood type by immature reticulocyte immunophenotype flow cytometry	2
Flow cytometric analysis of CD34⁺CD38⁻ cells; cell frequency and immunophenotype based on CD45RA expression pattern	2
ISSUE HIGHLIGHTS ‐ July 2020	2
Biclonality in hairy cell leukemia: Co‐occurrence of CD10⁺ and CD10⁻ clones with different surface membrane immunoglobulin expression	2
Applicability of the long‐term uncertainty in measurement (LTUM) method for analytical performance assessment in clinical cytometry laboratories	2
Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real‐world practice	2
Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS	2
The patterns and diagnostic significance of the lack of surface immunoglobulin light chain on mature B cells in clinical samples for lymphoma workup	2
Flow cytometry to detect bone marrow involvement by follicular lymphoma	2
Erythroid side scatter: A parameter that improves diagnostic accuracy of flow cytometry myelodysplastic syndrome scoring	2
Use of a hybrid intelligence decision tree to identify mature B‐cell neoplasms	2
Addition of formaldehyde releaser imidazolidinyl urea and MOPS buffer to urine samples enables delayed processing for flow cytometric analysis of urinary cells: A simple, two step conservat	2
The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease	2
Alignment, segmentation and neighborhood analysis in cyclic immunohistochemistry data using CASSATT	2
Dysplasia andPNH‐type cells in bone marrow aspirates of myelodysplastic syndromes	2
Increased IFN‐γ⁺ and TNF‐α⁺ mucosal‐associated invariant T cells in patients with aplastic anemia	2
Patients without cutaneous T‐cell lymphoma frequently harbor CD4 T‐lymphocytes that lack CD26 and/or CD7	2